About: Tercica     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:SocialGroup107950920, within Data Space : dbpedia.org:8891 associated with source document(s)
QRcode icon
http://dbpedia.org:8891/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FTercica

Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.

AttributesValues
rdf:type
rdfs:label
  • Tercica (en)
rdfs:comment
  • Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. (en)
foaf:name
  • Tercica, Inc. (en)
name
  • Tercica, Inc. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
fate
  • Acquired by Ipsen Group (en)
hq location city
hq location country
  • United States (en)
industry
successor
  • Ipsen Biopharmaceuticals, Inc. (en)
has abstract
  • Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1. Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency, which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD. In 2007, a case between Insmed and Tercica was settled when the jury found that Insmed infringed patents licensed to Tercica for Increlex. In the settlement, Insmed agreed to stop selling Iplex in the United States as a treatment for growth deficiencies and to withdraw an application to have the drug approved for such use in Europe. In 2008, the Ipsen Group acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc. (en)
prov:wasDerivedFrom
page length (characters) of wiki page
fate
  • Acquired byIpsen Group (en)
country
industry
location city
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 44 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software